Tocilizumab effectively reduces flares of hyperimmunoglobulin D syndrome in children

The clinical case data comes from the electronic medical record system and data obtained from telephone follow-up of the patients' mothers. This article provides a detailed introduction to the clinical data, laboratory tests, genetic results, and the diagnostic and treatment process of three patients with HIDS.

Specific descriptions and related data can be obtained in the article that is about to be published. Due to difficulties in obtaining interleukin-1 receptor antagonist (canakinumab) and side effects related to canakinumab in patient 2, all three HIDS patients were ultimately treated with interleukin-6 receptor antagonist (Tocilizumab). This treatment effectively reduced the occurrence of fever, lowered peripheral blood inflammatory indicators, and improved the patients' quality of life, providing both theory and practice for the application of interleukin-6 receptor antagonists in HIDS.